Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
1(8%)
Results Posted
29%(2 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_3
3
25%
Ph phase_1
6
50%
Ph phase_2
2
17%

Phase Distribution

6

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
6(54.5%)
Phase 2Efficacy & side effects
2(18.2%)
Phase 3Large-scale testing
3(27.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(1)
Completed(7)
Terminated(2)
Other(2)

Detailed Status

Completed7
unknown2
Terminated1
Active, not recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
87.5%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (54.5%)
Phase 22 (18.2%)
Phase 33 (27.3%)

Trials by Status

terminated18%
unknown217%
active_not_recruiting18%
withdrawn18%
completed758%

Recent Activity

1 active trials
Showing 5 of 12
active_not_recruitingphase_2

Deflazacort Vs. Prednisolone in Acute-stage ABPA

NCT04227483
completedphase_3

Finding the Optimum Regimen for Duchenne Muscular Dystrophy

NCT01603407
terminatedphase_3

A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)

NCT03783923
unknownphase_1

Study of the Excretion of Orally Administered Corticosteroids for the Improval of the Detection of Said Substances in Anti-doping Controls

NCT04791345
withdrawnphase_3

A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD)

NCT03642145
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT04227483Phase 2

Deflazacort Vs. Prednisolone in Acute-stage ABPA

Active Not Recruiting
NCT01603407Phase 3

Finding the Optimum Regimen for Duchenne Muscular Dystrophy

Completed
NCT03783923Phase 3

A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)

Terminated
NCT04791345Phase 1

Study of the Excretion of Orally Administered Corticosteroids for the Improval of the Detection of Said Substances in Anti-doping Controls

Unknown
NCT03642145Phase 3

A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD)

Withdrawn
NCT02592941

Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy

Unknown
NCT02295748Phase 1

An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort

Completed
NCT02485431Phase 1

Food Effect and Bioavailability of Deflazacort Formulations in Healthy Volunteers

Completed
NCT02286609Phase 1

A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics

Completed
NCT02286622Phase 1

A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics

Completed
NCT02251600Phase 1

A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy

Completed
NCT00527228Phase 2

Deflazacort in Dysferlinopathies

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12